Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rentokil initial pty ltd - aluminium phosphide - unknown - aluminium phosphide mineral-aluminium active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

upl australia pty ltd - aluminium phosphide - unknown - aluminium phosphide mineral-aluminium active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - aluminium phosphide - unknown - aluminium phosphide mineral-aluminium active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

national fumigants pty ltd - aluminium phosphide - unknown - aluminium phosphide mineral-aluminium active 0.0 - active constituent

New Zealand - English - Medsafe (Medicines Safety Authority)

johnson & johnson (new zealand) limited - aluminium hydroxide 80 mg/ml (added as aluminium / magnesium co-gel c655); magnesium hydroxide 80 mg/ml (added as aluminium / magnesium co-gel c655); simeticone 6 mg/ml (added as mg/ml of simethicone emulsion 30%) - oral suspension - active: aluminium hydroxide 80 mg/ml (added as aluminium / magnesium co-gel c655) magnesium hydroxide 80 mg/ml (added as aluminium / magnesium co-gel c655) simeticone 6 mg/ml (added as mg/ml of simethicone emulsion 30%) excipient: acesulfame potassium butyl hydroxybenzoate enhancer flavour fadp925 (natural sweetness) ethanol ethyl hydroxybenzoate mint flavour sn011397 propyl hydroxybenzoate purified water sorbitol xanthan gum xylitol

Israel - English - Ministry of Health

trupharm marketing 1985 ltd. - aluminium chloride hexahydrate - solution - aluminium chloride hexahydrate 20 %w/v - aluminium chlorohydrate - aluminium chlorohydrate - for the topical treatment of hyperhydrosis specifically involving axillae, hands or feet.

Australia - English - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - aluminium hydroxide,aluminium hydroxide hydrate,magnesium hydroxide,simethicone -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; sodium lauryl sulfate; ethylcellulose; polysorbate 80; magnesium stearate; hyprolose; purified talc; iron oxide yellow; povidone; light magnesium oxide; propylene glycol; titanium dioxide - rabeprazole is indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 80 mg - capsule, hard - excipient ingredients: hypromellose; sodium lauryl sulfate; gelatin; titanium dioxide; poloxamer; microcrystalline cellulose; sucrose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 125 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; sucrose; hypromellose; poloxamer; gelatin; sodium lauryl sulfate; titanium dioxide; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.